![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 25, 2021
This three-arm phase II study, led by Dr. Dan Zandberg, is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
February 28, 2020
January meeting with NCI leaders and the Cooperative Group Chairs; Congress increases NCI and overall NIH budget for FY 2020; EA opens two new trials, one for pancreatic cyst monitoring (EA2185) and the other to evaluate nivolumab in head and neck cancer (EA3161); plans are underway for the next Comis Symposium
February 28, 2020
This trial is evaluating maintenance nivolumab versus observation following intensity-modulated radiation therapy and cisplatin